Ontology highlight
ABSTRACT:
SUBMITTER: Rohr-Udilova N
PROVIDER: S-EPMC5593629 | biostudies-literature | 2017 Aug
REPOSITORIES: biostudies-literature
Rohr-Udilova Nataliya N Klinglmüller Florian F Seif Martha M Hayden Hubert H Bilban Martin M Pinter Matthias M Stolze Klaus K Sieghart Wolfgang W Peck-Radosavljevic Markus M Trauner Michael M
Oncotarget 20170706 34
The tyrosine kinase inhibitor erlotinib targets the receptor of epidermal growth factor (EGFR) involved in development of hepatocellular carcinoma (HCC). Although inefficient in established HCC, erlotinib has been recently proposed for HCC chemoprevention. Since Cyp3A4 and Cyp1A2 enzymes metabolize erlotinib in the liver, the insights into the mechanisms of erlotinib effects on liver cells with maintained drug metabolizing activity are needed. We applied erlotinib to both commercially available ...[more]